Table 2.
Delivery strategies for different types of agents.
| Category of agents | Agent | Formulation | Ref. |
|---|---|---|---|
| Small molecule | Dexamethasone | PEG‒Dex conjugates | 19 |
| Methotrexate | Dextran sulfate‒MTX conjugates | 20 | |
| Methotrexate | Albumin‒MTX conjugates | 21 | |
| Methylprednisolone | Cyclodextrin‒α-methylprednisolone conjugates | 22 | |
| Dexamethasone | PEGylation liposomes | 23 | |
| Dexamethasone | DC8,9PC and DSPE-PEG liposomes | 24 | |
| Dexamethasone | PCL‒PEG micelles | 25 | |
| Methotrexate | SA-Dex-OA/MTX micelles | 26 | |
| Curcumin | HA-Cur micelles | 27 | |
| Methotrexate | MTX-loaded albumin nanoparticles | 28 | |
| Methotrexate | Au/Fe half-shell PLGA nanoparticles | 29 | |
| Nucleic acid | IL-1β siRNA | Lipidoid‒polymer hybrid nanoparticles | 30 |
| p65 siRNA | PCL‒PEI and PCL‒PEG micelles | 31 | |
| siRNA against BTK | PEG-b-PLGA nanoparticles | 32 | |
| TNF-α siRNA | PEGylated solid-lipid nanoparticles | 33 | |
| Peptide/protein | Core peptide | PEGylated liposomes | 34 |
| TNF-α antibody | Carboxymethyl cellulose microneedle | 35 | |
| Etanercept | HA crosslinked microneedle | 36 | |
| TRAIL | HSA‒TRAIL conjugates | 37 | |
| Tocilizumab | Gold nanoparticles | 38 |
PEG, polyethylene glycol; DC8,9PC, 1,2-bis (10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine; PCL‒PEG, poly(ethylene glycol)‒poly(ε-caprolactone); SA, sialic acid; OA, octadecanoic acid; PCL‒PEI, poly(ε-caprolactone)-polyetherimide; HA, hyaluronic acid; Cur, curcumin; PLGA, poly(lactic-co-glycolic acid); TRAIL, tumor necrosis factor (TNF)-related apoptosis-inducing ligand; HSA, human serum albumin.